1. Home
  2. Journal
  3. Retatrutide trial results explained
GLP-1 research

Retatrutide Trial Results Explained: Phase 2 and Phase 3

What the published and reported trials show, in plain English, and the limits of what they can tell you.

GLP-1 researchPublished Updated 3 min read696 words

Research disclaimer For educational purposes only. Products are supplied strictly for laboratory research use. Not medical advice. Not for human or animal consumption.

Summary

  • Phase 2 (New England Journal of Medicine, 2023): adults with obesity, up to 24.2% mean weight reduction at 48 weeks in the highest dose group.
  • Phase 3, TRIUMPH-2: adults with type 2 diabetes and obesity or overweight, 80 weeks, reported mean weight reduction of 20.8% in the highest dose group.
  • Phase 3, TRIUMPH-3: adults with a BMI of 35 or more and established cardiovascular disease, 80 weeks, reported weight reduction of 22.6% in the highest dose group.
  • Safety: gastrointestinal events were the most commonly reported. In TRIUMPH-3, 13.5% in the highest dose group stopped treatment because of adverse events.
  • Regulatory: the developer has reported plans to file with the US FDA in the first quarter of 2027.

Phase 2 results

The phase 2 trial in adults with obesity was published in the New England Journal of Medicine in 2023 by Jastreboff and colleagues. It tested several dose levels against placebo over 48 weeks and reported dose dependent weight reduction, with up to 24.2% mean reduction in the highest dose group. It was the first large human dataset for the triple agonist.

Phase 3 TRIUMPH results

Phase 3 results were reported in 2026 for two trials. TRIUMPH-2 enrolled adults with type 2 diabetes and obesity or overweight and ran for 80 weeks. TRIUMPH-3 enrolled adults with a BMI of 35 or more and established cardiovascular disease, also over 80 weeks.

Reported weight reductions in the highest dose groups were 20.8% in TRIUMPH-2 and 22.6% in TRIUMPH-3. Weight loss in the placebo groups was far smaller. Cardiovascular outcome analyses in TRIUMPH-3 were described as not definitive.

In TRIUMPH-2, reported HbA1c reductions ranged from 1.4 to 1.6 percentage points across dose groups, against 0.2 with placebo.

Reported side effects in trials

Gastrointestinal effects such as diarrhoea, nausea and constipation were among the most commonly reported adverse events, which is typical of this class of peptides. In TRIUMPH-3, 13.5% of participants in the highest dose group stopped treatment because of adverse events. Trials record adverse events in far more detail than headlines do, so the published papers are the place to look.

How to read the percentages

Weight change can be reported with different statistical approaches. One estimates the effect in people who stayed on treatment, another includes everyone assigned to treatment. Both are valid and they give different numbers, so check which one a figure uses before comparing it with another trial.

Timeline of the programme

  • 2023: phase 2 results published in the New England Journal of Medicine.
  • 2026: phase 3 results reported for TRIUMPH-2 and TRIUMPH-3.
  • First quarter of 2027: the developer has reported plans to submit to the US FDA.

Trial terms explained

  • Placebo: an inactive comparison treatment.
  • Phase 2 and phase 3: phase 2 explores doses and early effects in a few hundred people. Phase 3 confirms results in larger groups.
  • HbA1c: a blood measure of average glucose over about three months, used in diabetes trials.
  • MACE: major adverse cardiovascular events such as heart attack and stroke.

Regulatory status

Retatrutide is investigational. Eli Lilly has reported plans to submit a Biologics License Application to the US FDA in the first quarter of 2027. Until a regulator approves a medicine, it has no licensed use.

What the trials do not show

These are trials of an investigational medicine given under medical supervision to selected participants. They do not describe laboratory research materials, do not establish equivalence between any supplied product and the trial drug, and say nothing about unsupervised use. Cambridge Health supplies [[retatrutide for laboratory research|/retatrutide]] only. See also [[how retatrutide compares with tirzepatide and semaglutide|/blog/retatrutide-vs-tirzepatide-semaglutide]].

References and evidence context

Jastreboff et al., Triple-hormone-receptor agonist retatrutide for obesity, a phase 2 trial, New England Journal of Medicine, 2023

HCPLive, Retatrutide meets phase 3 weight loss endpoints in 2 obesity trials, 2026

Manufacturing Chemist, Eli Lilly retatrutide hits phase III goals, FDA filing planned for 2027

Figures above are as reported in these sources at the time of writing. Check the published papers for full methods, confidence intervals and safety tables. Clinical research concerns the investigational material used in those trials. It does not establish equivalence, approval or suitability for human use of products supplied here.

Frequently asked questions

What were the retatrutide phase 3 results?

Reported mean weight reductions in the highest dose groups were 20.8% in TRIUMPH-2 and 22.6% in TRIUMPH-3 at 80 weeks. Placebo groups lost far less. Cardiovascular outcome analyses were not definitive.

When will retatrutide be approved?

The developer has reported plans to file with the US FDA in the first quarter of 2027. Approval timing depends on regulators and cannot be predicted.

What side effects were reported in the trials?

Gastrointestinal effects such as diarrhoea, nausea and constipation were among the most common. In TRIUMPH-3, 13.5% of participants in the highest dose group stopped treatment because of adverse events.

Does the trial data apply to research peptides?

No. The trials used an investigational medicine under medical supervision. They do not establish equivalence with, or suitability of, laboratory research materials.

Important information

Research use only. Not a medicine, not a supplement, not approved for human or animal use.

Cambridge Health™ does not provide usage, dosage, reconstitution or administration guidance for any product. Product information on this page is provided for research and educational context only.

  • Supplied strictly for laboratory and analytical research use. Not for human or animal consumption.
  • No medical advice, treatment guidance or personal use recommendations are provided.
  • Buyers are solely responsible for ensuring that the purchase, import, handling and use of research materials is lawful in their jurisdiction.

Supplied for laboratory research use only. Not a licensed medicine and not approved for human or animal use.

Related

Enquire about research supply

Cambridge Health supplies retatrutide research vials and the RetaPen for laboratory research. Submit a purchase request to discuss availability.

Submit a purchase request Chat on Telegram

Enquire about research supply

Cambridge Health supplies research peptides to UK laboratories. Submit a research enquiry to discuss availability.

Chat on Telegram